Monthly Prescribing Reference3d
Novel PCSK9 Inhibitor Lerodalcibep Under Review for Patients Requiring LDL-C Reduction
Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
pharmaphorum1d
AstraZeneca throws its hat into the oral PCSK9 ring
AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...
The Scientist5y
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
In the past few years, pharmaceutical companies have produced a class of drugs that lower cholesterol by inhibiting a protein called PCSK9 in a new attempt to reduce the risk of heart disease, the ...
pharmaphorum2y
AZ chases after PCSK9 rivals with antisense drug
AstraZeneca's take on the PCSK9 inhibitor – an antisense drug licensed from Ionis six years ago – has cleared a proof-of-concept trial in high-risk patients with high blood cholesterol ...
BioWorld11d
New PCSK9 inhibitors disclosed in Hansoh patent
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors acting as LDL-lowering agents ...
Business Wire4d
LIB Therapeutics Announces FDA Acceptance of Biologics License Application for Lerodalcibep to Lower LDL-Cholesterol Across Broad Patient Population
Lerodalcibep is a novel, adnectin-based, small protein-binding, third-generation PCSK9 inhibitor, with long-ambient stability, developed as a more patient-friendly, once-monthly, self-administered ...